BARBARA GAYLE DUNCAN
CIK 1353128 · Chief Accounting Officer · last filed 2026-05-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.47M
Companies
13
Total Filings
94
Lifetime Open-Market Net
-$6.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HTI | Director | 23,715 | — | — | $0 | 5 | 2026-05-07 |
| OVID | Director | — | $2.30 | — | $0 | 15 | 2026-03-02 |
| AVIR | Director | 62,750 | $4.49 | $281.7K | $0 | 7 | 2025-06-24 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 0 | $1.88 | $0 | -$256.2K | 10 | 2023-05-04 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 3 | 2022-07-01 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 0 | — | — | $0 | 7 | 2020-10-23 |
| ASND | Director | — | $218.06 | — | $0 | 3 | 2019-07-03 |
| Aevi Genomic Medicine, LLC (GNMX) Delisted | Director | 59,524 | — | — | $75.0K | 4 | 2018-07-18 |
| INVA | Director | 52,318 | $22.74 | $1.19M | $0 | 2 | 2017-04-24 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Chief Accounting Officer | 30,661 | $19.00 | $582.6K | -$6.80M | 25 | 2016-10-05 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | — | — | — | $0 | 2 | 2015-08-06 |
Recent Filings · Page 8 of 10
94 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-07-23 | Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-07 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +1,245 | -$12.5K | EDGAR |
| 2015-07-06 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | — | -$233.4K | EDGAR |
| 2015-04-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +1,259 | -$10.8K | EDGAR |
| 2015-04-01 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −1,000 | -$289.8K | EDGAR |
| 2015-01-07 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Sell (S) | −141 | -$24.9K | EDGAR |
| 2015-01-05 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +1,298 | -$124.5K | EDGAR |
| 2014-10-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | +1,299 | -$201.2K | EDGAR |
| 2014-07-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Exer (M) | +1,298 | $0 | EDGAR |
| 2014-01-17 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Mixed | — | -$1.28M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.